$124.04
0.56% yesterday
Nasdaq, May 23, 09:49 pm CET
ISIN
US89377M1099
Symbol
TMDX

TransMedics Group, Inc. Stock price

$124.25
+32.00 34.69% 1M
+45.67 58.12% 6M
+61.90 99.28% YTD
-13.28 9.66% 1Y
+96.24 343.59% 3Y
+108.25 676.56% 5Y
+108.25 676.56% 10Y
Nasdaq, Closing price Fri, May 23 2025
+0.91 0.74%
ISIN
US89377M1099
Symbol
TMDX
Sector

Key metrics

Market capitalization $4.20b
Enterprise Value $4.40b
P/E (TTM) P/E ratio 101.84
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.02
P/S ratio (TTM) P/S ratio 8.61
P/B ratio (TTM) P/B ratio 15.78
Revenue growth (TTM) Revenue growth 64.43%
Revenue (TTM) Revenue $488.23m
EBIT (operating result TTM) EBIT $52.52m
Free Cash Flow (TTM) Free Cash Flow $-63.23m
Cash position $310.14m
EPS (TTM) EPS $1.22
P/E forward 68.38
P/S forward 7.24
EV/Sales forward 7.59
Short interest 44.92%
Show more

Is TransMedics Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

TransMedics Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

Buy
70%
Hold
30%

Financial data from TransMedics Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
488 488
64% 64%
100%
- Direct Costs 198 198
77% 77%
41%
290 290
57% 57%
59%
- Selling and Administrative Expenses 176 176
37% 37%
36%
- Research and Development Expense 62 62
10% 10%
13%
53 53
474% 474%
11%
- Depreciation and Amortization 0.30 0.30
200% 200%
0%
EBIT (Operating Income) EBIT 53 53
469% 469%
11%
Net Profit 49 49
580% 580%
10%

In millions USD.

Don't miss a Thing! We will send you all news about TransMedics Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransMedics Group, Inc. Stock News

Positive
Seeking Alpha
3 days ago
TransMedics delivered a stellar Q1, beating revenue and EPS estimates, and raised FY25 guidance, showcasing robust growth and execution. I see significant upside from expanding organ utilization, especially with the upcoming kidney market and international opportunities, which meaningfully increase TAM. Despite risks like share dilution, logistics complexity, and regulatory hurdles, TMDX's moat...
Neutral
PRNewsWire
4 days ago
ANDOVER, Mass. , May 20, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
Positive
The Motley Fool
10 days ago
While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more.
More TransMedics Group, Inc. News

Company Profile

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

Head office United States
CEO Waleed Hassanein
Employees 728
Founded 1998
Website www.transmedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today